Global Blood Cancer Diagnostics Market to Grow at 6.4% CAGR Through 2022 | Abbott Laboratories, Thermo Fisher Scientific Inc., Roche Holding A.G.

Fact.MR, in its recent research, offers market forecast and analysis on the blood cancer diagnostics market for the period, 2017-2022.
According to the research, the global blood cancer diagnostics market is projected to grow at 6.4% CAGR through 2022.

Click here to Get Complete Synopsis of the Report – https://www.factmr.com/report/47/blood-cancer-diagnostics-market

The key takeaways from Fact.MR’s research report include,
• By test type, the CBC segment, which is currently valued at nearly US$ 77 million, is projected to grow at nearly 5% CAGR. In the North America blood cancer diagnostics market, these tests will continue to account for a significant share of overall revenues.
• Owing to highly accurate diagnosis, blood testing will also continue to be a widely used test globally. Fact.MR projects this segment to rake in significant revenues by 2022.

For detailed insights on enhancing your product footprint, request for a sample here - https://www.factmr.com/connectus/sample?flag=S&rep_id=47

• On back of recent reports about the accuracy and benefits of using liquid biopsy, this segment is gaining traction globally. Research carried out at Massachusetts General Hospital Cancer Center and Harvard Medical School has shown that liquid biopsy can help patients with advanced cholangiocarcinoma. Fact.MR projects this segment to grow at a high CAGR through 2022.
• The bone marrow test type is also being widely used by end-users owing to its efficacy in diagnosis and management. According to Fact.MR’s analysis, the bone marrow test type is anticipated to rake in significant revenues during the forecast period. Revenues from this segment are anticipated to grow at a healthy CAGR through 2022.

For critical insights on this market, request for methodology here - https://www.factmr.com/connectus/sample?flag=RM&rep_id=47

• Hospital associated labs account for a significant revenue share of the overall demand for blood cancer diagnostics. According to Fact.MR’s analysis, this end-use segment is projected to grow at over 6% CAGR through 2022.
• Independent diagnostic laboratories are also a major end-user of blood cancer diagnostics. Fact.MR estimates revenues from this segment to grow at over 6% CAGR through 2022. Demand is also anticipated to be strong from the cancer research institutes segment.
• The blood cancer diagnostics market in the U.S. will continue to account for a significant share of the global revenues. The U.S. will also remain significant owing to R&D and new developments in diagnostics. Fact.MR projects the U.S. blood cancer diagnostics market to account for leading revenue share of the global market.

For in-depth competitive analysis, buy now - https://www.factmr.com/checkout/47

• In Europe, Germany and U.K. will account for significant revenue share of the global revenues. Advancements in R&D, combined with increasing prevalence of the disease will hamper growth of the market.
• Leading companies in the market are focusing on investing in R&D to come up with innovative and accurate diagnostics solutions. Mergers and acquisitions, and collaborations will continue to remain a trend in this market.

Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2019/09/11/1914156/0/en/Ill-Effects-of-Self-medication-Practices-to-Ramp-up-the-Adoption-of-Earwax-Removal-Aids-Fact-MR.html

Market Taxonomy

Test Type

CBC Tests
CTC Tests
Blood Protein Testing
Liquid Biopsy
Bone Marrow Biopsy

Others

End User Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others

For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=47

The report has also profiled key players in the global market for blood cancer diagnostics, which include companies such as Abbott Laboratories, Thermo Fisher Scientific Inc., Roche Holding A.G., Laboratory Corporation of America Holdings, Luminex Corporation, NanoString Technologies Inc, Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, Siemens AG, Qiagen N.V., Biotheranostics, Inc, Agilent Technologies, Almac Group Limited, and GeneNews Limited.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Content Source: https://www.factmr.com/media-release/33/global-blood-cancer-diagnostics-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.